TrialJBMR plus2026

Palovarotene impact on fibrodysplasia ossificans progressiva (FOP): data from month 48 of the phase III MOVE trial.

Robert J Pignolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.